BRCA1 and ovarian carcinoma: Recently, therapeutic advances incorporating PARP and VEGF inhibitors into upfront and maintenance therapy show promising results in BRCA-mutated and other homologous recombination deficiency (HRD) cancers [5,6], but only 10–14% of women with epithelial ovarian cancer have a germline mutation in BRCA1 or 2 [7].